PerkinElmer Inc, Waltham, Mass, a global leader focused on improving the health and safety of people and the environment, recently received clearance from the China Food and Drug Administration to bring to market its genetic screening processor (GSP) and GSP neonatal hTSH reagent kit.
The GSP is a fully automated, high-throughput analyzer that tests neonatal dried bloodspot samples to detect potentially life-threatening conditions in newborn babies. The instrument can test for a wide array of disorders, using the company’s dried bloodspot assays on the same platform. The neonatal hTSH reagent kit, newly cleared for the Chinese market, aids in the detection of congenital hypothyroidism.
According to PerkinElmer, the company is looking to bring a broader menu of GSP assays to China.
“We are committed to developing innovative solutions to help newborn screening labs in China respond to rising birth rates and expand access to testing for serious health risks in newborn babies,” says Johnson Zhang, vice president and general manager for Asia-Pacific diagnostics at PerkinElmer. “As China seeks to improve the efficiency of newborn screening and reduce false-positive and false-negative rates, our advanced detection technologies are designed to deliver highly reliable results for better outcomes.”
The expandable GSP instrument provides laboratories with the ability to automate every stage of an assay, from specimen reception to results reporting. In addition, PerkinElmer’s informatics software enhances automation of the newborn screening process, integrating additional assays, analytical instruments, and punchers with the GSP platform.
For more information, visit PerkinElmer.
